Join
Live feed
·
PRReleasevia Quantisnow
Castle Biosciences Inc. logo

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

ByQuantisnow·Wall Street's wire, on your screen.
CSTL· Castle Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CSTL (Castle Biosciences Inc.) and more on Quantisnow.